BioCentury’s 2021 Class of Emerging Companies
February 14, 2022
An innovation showcase of protein degraders, RNA therapeutics, delivery vectors and gene modifiers
News + Press
Explore by Category
Select
Interius’ Senior Director of Analytical Development to Speak at 14th Annual Bioprocessing Summit
November 01, 2022
An innovation showcase of protein degraders, RNA therapeutics, delivery vectors and gene modifiers
The BrightEdge Fund 2021 Annual Review
November 01, 2022
An innovation showcase of protein degraders, RNA therapeutics, delivery vectors and gene modifiers
Interius Named as Finalist for the Deal of the Year Award by Life Sciences Pennsylvania
November 01, 2022
An innovation showcase of protein degraders, RNA therapeutics, delivery vectors and gene modifiers
BioCentury’s 2021 Class of Emerging Companies
February 14, 2022
An innovation showcase of protein degraders, RNA therapeutics, delivery vectors and gene modifiers
Interius Bio Announces Granting of US Patent to Support in Vivo Cell-Specific Gene Delivery Platform
December 09, 2021
Company also celebrates “Deal of the Year” awarded by The Penn Center for Innovation PHILADELPHIA,…
Pennovation Lab Welcomes New Tenant Interius BioTherapeutics to Its Innovation Ecosystem
October 05, 2021
Penn Cell and Gene Therapy Spinout Interius Biotherapeutics Raises $76 Million
May 18, 2021
Interius BioTherapeutics Raises $76M Series A Financing to Advance Breakthrough Cell and Gene Therapy Platform
May 18, 2021
Interius BioTherapeutics, a preclinical stage gene therapy company developing a paradigm-shifting platform for in vivo cell-specific gene delivery, today announced that it has raised $76 million in an oversubscribed Series A financing.